Biodesix Inc. (BDSX) Misses Q2 EPS by 1c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BDSX Hot Sheet
Join SI Premium – FREE
Biodesix Inc. (NASDAQ: BDSX) reported Q2 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $20 million versus the consensus estimate of $18.49 million.
GUIDANCE:
Biodesix Inc. sees FY2025 revenue of $80-85 million, versus the consensus of $82.02 million.
For earnings history and earnings-related data on Biodesix Inc. (BDSX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ADMA Biologics (ADMA) Tops Q3 EPS by 3c
- Allient Inc. (ALNT) Tops Q3 EPS by 33c, Beats on Revenue
- Edwards Lifesciences (EW) Tops Q3 EPS by 6c; raises guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
